Politics / Law

Study says EU policymakers can not uphold zero tolerance policy towards non EU-approved GM-crops

14.07.2009

Brussels/Seville – Results of a brand-new study suggest that the EU will soon have to accept food and feed imports that carry tiny amounts of genetically modified organisms (GMOs) not yet approved by the EU authorities. Otherwise prices might rise soon, according to the analysis of the EU’s think tank, the Institute of Prospective Research (ISPRA) in Seville, Spain. The asynchronous approval of GM crops, which is caused by national differences in regulation and political approval of GMOs, is at the heart of the problem, say the researchers.
Even today, global seed traders face the economic risk of shipment rejections at the EU borders, because the EU currently does not accept any admixtures with GM crops that haven’t been approved by the EU authorities. And that problem could intensify because the number of GM crops approved outside the EU will quadruple to 120 by 2015, the study suggests (for GMO pipeline see ipts.jrc.ec.europa.eu/publications/pub.cfm. When complying with a zero tolerance policy for unapproved GMOs becomes impossible, exporters may only deal with "preferred buyers" who are known to create little problems, according to the ISPRA researchers.
The study backs claims of seed traders organised in the European Feed Manufacturers’ Federation (FEFAC) that is lobbying for a 0.9% tolerance threshold for all non EU-approved GMOs that have been safety-checked by authorities in line with the World Health Organisation’s (WHO) Codex Alimentarius GM plant guideline.
Experts told EuroBiotechNews that an economic problem for the EU may arise, when it comes to asynchronous approvals of GM soy lines, because the EU is dependent on imports of Argentinia (42% of imports) and Brazil (45% of imports). According to the study, 9 new genetically engineered soy lines can enter the market by 2015, one of them an insect-resistant soybean filed for approval in China.
The Commission has already recognised the problem. Last summer, Health Commissioner Androulla Vassiliou announced that the Commission will be proposing a threshold that would allow food and feed to enter the EU even if it contains traces of unauthorised genetically modified organisms (GMOs). But up to now nothing has happened.


Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/study-says-eu-policymakers-can-not-uphold-zero-tolerance-policy-towards-non-eu-approved-gm-crops.html

Product of the week

Products

Events

All Events

Current issue

All issues